What kind of company is Intra-Cellular Therapies?

Intra-Cellular Therapies is a biopharmaceutical company that focuses on developing innovative therapies for neuropsychiatric and neurological disorders. The company was founded in 2002 by Dr. Allen A. Fienberg, a renowned psychiatrist, and neuroscientist.

Intra-Cellular Therapies is known for its research in the field of schizophrenia and bipolar disorder. The company's lead drug candidate, lumateperone, is an investigational oral medication designed to treat schizophrenia by selectively targeting specific neurotransmitter receptors in the brain. Lumateperone has shown promising results in clinical trials, with the potential to improve the lives of patients suffering from this debilitating condition.

In addition to lumateperone, Intra-Cellular Therapies has a robust pipeline of drug candidates in various stages of development for other neuropsychiatric and neurological disorders, including major depressive disorder, Parkinson's disease, and Alzheimer's disease.

The company is dedicated to advancing the field of neuropsychiatric medicine and improving the lives of patients suffering from these complex conditions. Intra-Cellular Therapies is committed to conducting rigorous research, collaborating with leading experts in the field, and bringing innovative therapies to the market to address significant unmet medical needs.